马斯克的脑机接口公司最新计划：每年为2万人植入芯片

Group 1 - Neuralink aims to implant brain chips in approximately 20,000 people annually by 2031, targeting an annual revenue of at least $1 billion [1] - The company plans to establish at least five large clinical centers for brain-machine interfaces within the next six years and launch three product lines: Telepathy, Blindsight, and Deep [1][2] - The projected revenue breakdown includes $100 million from 2,000 implants of the Telepathy version in 2029, $500 million from 10,000 Blindsight implants in 2030, and over $1 billion from 20,000 Deep implants for Parkinson's treatment [1] Group 2 - Since its establishment in 2016, Neuralink has raised approximately $1.3 billion, achieving a valuation of around $9 billion [2] - The company received FDA breakthrough device designation in May 2023, allowing it to conduct human clinical trials, with the first patient successfully implanted in January 2024 [2] - Neuralink's technology focuses on a closed-loop system of "implant-read-feedback-process," which is crucial for its commercialization strategy [2] Group 3 - The global brain-machine interface market is projected to grow from $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 16.48% [4] - Neuralink faces challenges including the risks associated with deep brain implantation, concerns over brain data privacy, and competition from companies like Synchron and Precision Neuroscience [4] - The success of Neuralink's strategic goals will test its capabilities in technology, safety, ethics, regulation, and market dynamics, potentially marking a turning point in the brain-machine interface era [4]